Merck & Co. joins race for COVID-19 vaccines and therapies

The firm will develop viral vector vaccines from IAVI and Themis Bioscience, and the experimental EIDD-2801 antiviral compound developed by Ridgeback Biotherapeutics

Source: Chemical and Engineering News - May 27, 2020 Category: Chemistry Authors: Ryan Cross Source Type: research